AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30033790 — intervention group
Group type: COMPARATOR
Intervention: Written materials prepared by the professor - lecture content before class
Number of subjects: 100
Study 26646803 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2) received 1 L of PEG in the day before SBCE and 1 L of PEG in the morning before SBCE (time between PEG and SBCE=4 h)
Number of subjects: 57
Study 26646803 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (G1) received 2 L of PEG in the day before SBCE (time between PEG and SBCE=10 h)
Number of subjects: 57
Study 26646803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PEG regimens
Number of subjects: 57
Study 24160904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment plus standard wound care
Number of subjects: 39
Study 24160904 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment plus standard wound care
Number of subjects: 39
Study 21930549 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula (N = 50)
Number of subjects: 107
Study 21930549 — intervention group
Group type: COMPARATOR
Intervention: Control formula (N = 57)
Number of subjects: 107
Study 18654867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 121
Study 18654867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg (after dosage increase)
Number of subjects: 121
Study 18654867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg with compliance enhancement tools
Number of subjects: 121
Study 18654867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 121
Study 18654867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (both dosages)
Number of subjects: 121
Study 16339344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (Water)
Number of subjects: 12
Study 16339344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice packs covering the upper legs (Packs)
Number of subjects: 12
Study 16339344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice vest (Vest)
Number of subjects: 12
Study 16339344 — intervention group
Group type: COMPARATOR
Intervention: No cooling (Control)
Number of subjects: 12
Study 14501815 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate (GnRH agonist) for 3 months
Number of subjects: 71
Study 14501815 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 71
Study 10898414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation (gamma and beta emitters), maximum dose to the vessel wall was 30 to 55 Gy, followed by antiplatelet therapy (aspirin and either ticlopidine or clopidogrel for one month).
Number of subjects: 473
Study 10898414 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no radiation), followed by antiplatelet therapy (aspirin and either ticlopidine or clopidogrel for one month).
Number of subjects: 473
Study 9372677 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg in 250 ml D5W
Number of subjects: 4
Study 9372677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON) 250 ml D5W
Number of subjects: 4
Study 9372677 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 4
Study 9372677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 4
Study 1401389 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving skills training (PSST)
Number of subjects: 97
Study 1401389 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent management training (PMT)
Number of subjects: 97
Study 1401389 — intervention group
Group type: EXPERIMENTAL
Intervention: PSST and PMT combined
Number of subjects: 97
Study 1401389 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97
Study 2427393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral urokinase
Number of subjects: 101
Study 2427393 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 101
Study 30613009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ronghuang granule (3 times a day)
Number of subjects: 70
Study 30613009 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment combined with traditional Chinese medicine retention enema (Control)
Number of subjects: 70
Study 27418333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration contrast agents (270 and 320 mg iodine/ml)
Number of subjects: 318
Study 27418333 — intervention group
Group type: COMPARATOR
Intervention: High-concentration contrast agent (370 mg iodine/ml)
Number of subjects: 318
Study 24328248 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS simulation scenario, 4-hour PowerPoint presentation, and demonstration on a static manikin
Number of subjects: 82
Study 24328248 — intervention group
Group type: COMPARATOR
Intervention: PowerPoint presentation and demonstration only (Control)
Number of subjects: 82
Study 22916818 — intervention group
Group type: COMPARATOR
Intervention: 20 g isolated yellow pea protein (P20)
Number of subjects: 39
Study 22916818 — intervention group
Group type: COMPARATOR
Intervention: 10 g isolated yellow pea protein (P10)
Number of subjects: 39
Study 22916818 — intervention group
Group type: COMPARATOR
Intervention: 10 g isolated yellow pea fibre (F10)
Number of subjects: 39
Study 22916818 — intervention group
Group type: COMPARATOR
Intervention: 20 g isolated yellow pea fibre (F20)
Number of subjects: 39
Study 22916818 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 39
Study 20567163 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping repair
Number of subjects: 149
Study 20567163 — intervention group
Group type: COMPARATOR
Intervention: End-to-end repair
Number of subjects: 149
Study 20567163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 149
Study 18678301 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-778,875 2 mg/day
Number of subjects: 86
Study 18678301 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-778,875 0.5, 2, or 6 mg/day
Number of subjects: 86
Study 18678301 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-778,875 6 mg/day
Number of subjects: 86
Study 18678301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 19158541 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency TENS (100 Hz)
Number of subjects: 64
Study 19158541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency TENS (4 Hz)
Number of subjects: 64
Study 19158541 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 64
Study 15750197 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 241
Study 15750197 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 241
Study 15750197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 241
Study 12027463 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune modulation therapy (IMT) - 10 ml of citrated autologous blood administered by intra-muscular injection after exposure to UV light and oxidisation, 6 injections over 3 weeks followed by 3 weeks rest, with 2-4 courses depending on response.
Number of subjects: 70
Study 12027463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 12027463 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune modulation therapy (IMT) - subgroup analysis for short distance claudicants
Number of subjects: 70
Study 12027463 — intervention group
Group type: COMPARATOR
Intervention: Placebo - subgroup analysis for short distance claudicants
Number of subjects: 70
Study 15613167 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol nasal spray 1 mg followed by optional second 1 mg dose
Number of subjects: 321
Study 15613167 — intervention group
Group type: COMPARATOR
Intervention: Fiorinal with Codeine (one capsule containing butalbital 50 mg, caffeine 40 mg, aspirin 325 mg, and codeine phosphate 30 mg)
Number of subjects: 321
Study 7609510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 4800
Study 7609510 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 4800
Study 3303427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol A (Turret nebuliser, MMD 1.8 micron)
Number of subjects: 6
Study 3303427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol B (Upmist nebuliser, MMD 4.6 microns)
Number of subjects: 6
Study 3303427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol C (Inspiron Mini-neb, MMD 10.3 microns)
Number of subjects: 6
Study 28535964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low income
Number of subjects: 381
Study 28535964 — intervention group
Group type: COMPARATOR
Intervention: Low educational level
Number of subjects: 381
Study 28535964 — intervention group
Group type: COMPARATOR
Intervention: High perceived stress
Number of subjects: 381
Study 27008577 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ropivacaine (injected at three portal sites and atomized in the abdominal cavity)
Number of subjects: 187
Study 27008577 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ropivacaine
Number of subjects: 187
Study 27008577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 24760248 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (500 mg twice a day)
Number of subjects: 92
Study 24760248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23304972 — intervention group
Group type: EXPERIMENTAL
Intervention: RME activation protocols
Number of subjects: 60
Study 20479546 — intervention group
Group type: EXPERIMENTAL
Intervention: GPD (gemcitabine, dexamethasone, cisplatine)
Number of subjects: 96
Study 20479546 — intervention group
Group type: COMPARATOR
Intervention: ESHAP (etoposide, cisplatine, solumedrol, aracytine)
Number of subjects: 96
Study 20479546 — intervention group
Group type: EXPERIMENTAL
Intervention: GPD
Number of subjects: 96
Study 20479546 — intervention group
Group type: COMPARATOR
Intervention: ESHAP
Number of subjects: 96
Study 18714603 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered caregiving training (2-hour program)
Number of subjects: 0
Study 18714603 — intervention group
Group type: COMPARATOR
Intervention: Control group (students who did not complete the training)
Number of subjects: 0
Study 15683891 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 75
Study 15683891 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Number of subjects: 75
Study 15683891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination neomycin‐polymyxin B‐hydrocortisone
Number of subjects: 75
Study 15683891 — intervention group
Group type: COMPARATOR
Intervention: Positive control (no intracanal medicament)
Number of subjects: 75
Study 15683891 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no endotoxin and no intracanal medicament)
Number of subjects: 75
Study 12598751 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic RFA
Number of subjects: 23
Study 12598751 — intervention group
Group type: COMPARATOR
Intervention: RFA via laparotomy
Number of subjects: 23
Study 12598751 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous RFA
Number of subjects: 23
Study 10589274 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 1663
Study 10589274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1663
Study 10589274 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1663
Study 8614496 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 83
Study 2018818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral electrostimulation (electrosleep)
Number of subjects: 21
Study 2018818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7328569 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of levamisole on 3 consecutive days
Number of subjects: 100
Study 7328569 — intervention group
Group type: COMPARATOR
Intervention: 150 mg of levamisole once weekly
Number of subjects: 100
Study 31927219 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical strategies PFI
Number of subjects: 268
Study 31927219 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy norms PFI
Number of subjects: 268
Study 31927219 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (AOC)
Number of subjects: 268
Study 29943890 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 6214
Study 26620373 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil rich in docosahexanoic acid (DHA)
Number of subjects: 54
Study 26620373 — intervention group
Group type: COMPARATOR
Intervention: Conventional canola oil (Canola)
Number of subjects: 54
Study 26620373 — intervention group
Group type: COMPARATOR
Intervention: High-oleic acid canola oil (CanolaOleic)
Number of subjects: 54
Study 24768155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry plus clinical assessment
Number of subjects: 122738
Study 24768155 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 122738
Study 24768155 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximetry alone
Number of subjects: 122738
Study 22301338 — intervention group
Group type: EXPERIMENTAL
Intervention: PU stent
Number of subjects: 50
Study 22301338 — intervention group
Group type: COMPARATOR
Intervention: PE stent
Number of subjects: 50
Study 20053398 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg of oral mifepristone followed by 400 microg of oral misoprostol (group 1)
Number of subjects: 252
Study 20053398 — intervention group
Group type: COMPARATOR
Intervention: 800 microg of sublingual misoprostol repeated every 4 hours for up to a maximum of 3 doses (group 2)
Number of subjects: 252
Study 18853552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus diameter of 62 degrees
Number of subjects: 0
Study 18853552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus diameter of 30 degrees
Number of subjects: 0
Study 18853552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus diameter of 5 degrees
Number of subjects: 0
Study 18853552 — intervention group
Group type: COMPARATOR
Intervention: Same-eye adapt/test durations
Number of subjects: 0
Study 16468528 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg preoperatively
Number of subjects: 80
Study 16468528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15211533 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy (5000 lux for 50 minutes per day for 5 days)
Number of subjects: 0
Study 15211533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 10858728 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with diabetes duration of 1-2.5 years
Number of subjects: 32
Study 10858728 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with diabetes duration of 4 years
Number of subjects: 32
Study 10858728 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with diabetes duration of 5-27 years (Group 2)
Number of subjects: 32
Study 10858728 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with chronic neurogenic symptoms
Number of subjects: 32
Study 10858728 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with carpal tunnel syndrome
Number of subjects: 32
Study 9386203 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 100% maximum power output
Number of subjects: 0
Study 9386203 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 70% maximum power output
Number of subjects: 0
Study 9386203 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study 1493624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum + nifedipine
Number of subjects: 40
Study 1493624 — intervention group
Group type: COMPARATOR
Intervention: Cisplatinum
Number of subjects: 40
Study 4034296 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous growth hormone therapy
Number of subjects: 20
Study 4034296 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular growth hormone therapy
Number of subjects: 20
Study 31870046 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO) through anterior approach (group A)
Number of subjects: 76
Study 31870046 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive plate osteosynthesis (MIPO) through lateral approach (group B)
Number of subjects: 76
Study 29996928 — intervention group
Group type: EXPERIMENTAL
Intervention: Global engagement strategy involving all health professionals from the beginning
Number of subjects: 0
Study 29996928 — intervention group
Group type: COMPARATOR
Intervention: Sequential engagement strategy starting with nurses then involving doctors
Number of subjects: 0
Study 29996928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 0
Study 27094945 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06743649 (40 mg dose)
Number of subjects: 0
Study 27094945 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06743649
Number of subjects: 0
Study 27094945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25143717 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 50
Study 25143717 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (PT)
Number of subjects: 50
Study 22891748 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg once a week)
Number of subjects: 0
Study 22891748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once a week)
Number of subjects: 0
Study 22891748 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 19748247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall oil sterol margarine
Number of subjects: 59
Study 19748247 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed sterol margarine
Number of subjects: 59
Study 19748247 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 59
Study 18723857 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (100 microg kg(‐1) loading dose; 10-30 microg kg(‐1) h(‐1) infusion for 14 days)
Number of subjects: 898
Study 18723857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 898
Study 15759252 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinergy wheels
Number of subjects: 20
Study 15759252 — intervention group
Group type: COMPARATOR
Intervention: Standard steel-spoke wheels
Number of subjects: 20
Study 12658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (2 mg/day)
Number of subjects: 133
Study 12658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (4 mg/day)
Number of subjects: 133
Study 12658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75 microg/day)
Number of subjects: 133
Study 12658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg/day)
Number of subjects: 133
Study 12658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz
Number of subjects: 133
Study 12658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 133
Study 9804037 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisocial families (ADHD with comorbidity)
Number of subjects: 0
Study 9804037 — intervention group
Group type: COMPARATOR
Intervention: Non-antisocial families
Number of subjects: 0
Study 9804037 — intervention group
Group type: COMPARATOR
Intervention: Control families
Number of subjects: 0
Study 7641351 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional Coronary Atherectomy (DCA)
Number of subjects: 305
Study 7641351 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 305
Study 7641351 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA
Number of subjects: 305
Study 7641351 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of thrombus
Number of subjects: 305
Study 7641351 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal embolization
Number of subjects: 305
Study 2540785 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 17
Study 2540785 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (Control)
Number of subjects: 17
Study 339337 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobutane exposure at concentrations of 500 ppm for 1, 2, or 8 hours per day, five days per week for two weeks.
Number of subjects: 8
Study 339337 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobutane and propane mixtures for 1, 2, or 8 hours per day for two days.
Number of subjects: 8
Study 339337 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ECG telemetry and serial computerized spirometric measurements.
Number of subjects: 8
Study 339337 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial laboratory studies including complete blood count, urinalysis, serum alkaline phosphatase, SGOT, LDH, serum bilirubin, blood sugar, serum calcium, serum phosphorus, BUN, spontaneous electroencephalogram, visual evoked response, cognitive tests, ACTH stimulation test.
Number of subjects: 8
Study 31236689 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 52
Study 31236689 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive thoracoscopic PVI and left atrial appendage ligation (MIPI)
Number of subjects: 52
Study 31236689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CA and MIPI
Number of subjects: 52
Study 29032449 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Cognitive Behavioral Treatment (SHCBT)
Number of subjects: 55
Study 29032449 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 55
Study 27119581 — intervention group
Group type: EXPERIMENTAL
Intervention: Softgel capsule (diclofenac potassium 50 mg)
Number of subjects: 0
Study 27119581 — intervention group
Group type: COMPARATOR
Intervention: Oral solution (diclofenac potassium 50 mg)
Number of subjects: 0
Study 27119581 — intervention group
Group type: COMPARATOR
Intervention: Tablet (diclofenac potassium 50 mg)
Number of subjects: 0